US 11,666,580 B2
Mechanism of resistance to bet bromodomain inhibitors
Kornelia Polyak, Brookline, MA (US); Shaokun Shu, Brookline, MA (US); James E. Bradner, Weston, MA (US); and Charles Yang Lin, Houston, TX (US)
Assigned to Dana-Farber Cancer Institute, Inc., Boston, MA (US)
Appl. No. 15/751,914
Filed by Dana-Farber Cancer Institute, Inc., Boston, MA (US)
PCT Filed Aug. 10, 2016, PCT No. PCT/US2016/046318
§ 371(c)(1), (2) Date Feb. 12, 2018,
PCT Pub. No. WO2017/027571, PCT Pub. Date Feb. 16, 2017.
Claims priority of provisional application 62/203,128, filed on Aug. 10, 2015.
Prior Publication US 2020/0368248 A1, Nov. 26, 2020
Int. Cl. A61K 31/551 (2006.01); A61K 31/5415 (2006.01); A61K 45/06 (2006.01); G01N 33/574 (2006.01); A61P 35/00 (2006.01); A61K 31/137 (2006.01)
CPC A61K 31/551 (2013.01) [A61K 31/137 (2013.01); A61K 31/5415 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); G01N 33/57415 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A method for treating a cancer, the method comprising:
administering to a subject in need thereof a bromodomain and extra terminal (BET) inhibitor and a protein phosphatase 2A (PP2A) activator in an amount effective to treat the cancer, wherein the cancer is resistant to treatment by the BET inhibitor alone.